Table 1.

Summary characteristics of included studies

Reference	Country (years of intervention)	Study Design	Baseline Transmission	Reactive IRS		Outcomes Reported
				Insecticide (target dose) and Targeted Households	Number of Clusters, Population Targeted, and Coverage
Hsiang et al.7	Namibia (2017)	Cluster-randomized controlled trial, superiority design	35.9 Cases per 1,000 population per year	Pirimiphos-methyl (1 g/m2); up to seven households within 500 m of index case	Clusters = 28 Population = 9,464*; coverage of index houses = 81.6%; coverage of targeted houses = 93.3%; overall coverage = approximately one-third of houses	Cumulative incidence beginning 8 weeks after the first index case in each cluster; prevalence of infection in an endline survey; adverse events
Bath et al.6	South Africa (2015–2017)	Cluster-randomized controlled trial, noninferiority design	1–5 Cases per 1,000 person-years	Deltamethrin; up to eight households within 200 m of index case	Clusters = 31; population = 204,237; overall coverage in reactive IRS = 5%; overall coverage in proactive, focal IRS = 30%	Mean cluster-level incidence; adverse events (malaria deaths); contextual factors: financial and economic considerations

IRS = indoor residual spraying.

^*Estimated from average cluster size of 338.